Breast Surgery Bulletin - April 2022

 

Global guidelines for breast cancer screening: A systematic review

 

by Wenhui Ren, Mingyang Chen, Youlin Qiao, Fanghui Zhao 

 

The Breast: Published: April 19, 2022

 

Highlights

• This systematic review comprehensively maps the recommendations of the latest international breast screening guidelines, providing valuable tools for clinical decision-making in different settings.

• Most guidelines recommended biennial mammographic screening between 40 to 74 years for the average-risk populations and annual MAM or annual MRI starting from a younger age for the high-risk populations. However, there are indeed discrepancies in screening age and method among countries.

• High-quality evidence and rigorous methodology are the keys to guidance development, but current guidelines varied in methodological quality.

Summary

Breast cancer screening guidelines could provide valuable tools for clinical decision-making by reviewing the available evidence and providing recommendations. Little information is known about how many countries have issued breast cancer screening guidelines and the differences among existed guidelines. We systematically reviewed current guidelines and summarized corresponding recommendations, to provide references for good clinical practice in different countries.

International guidelines for management of metastatic breast cancer

International guidelines for management of metastatic breast cancer from the European School of Oncology - MBC Task Force: Surveillance, staging and evaluation of patients with early-stage and metastatic breast cancer. The breast, June 2013, Vol. 22(3), p.203-10

Lin, N.U, et al.

http://www.thebreastonline.com/article/S0960-9776(13)00062-3/abstract

In clinical practice, the surveillance and follow-up of patients with breast cancer (BC) is quite variable. At the 7th European Breast Cancer Conference, the ESO-MBC Task Force convened a series of lectures, followed by open debate, on the use of physical examination, imaging, and laboratory tests in patients with early-stage BC, and for restaging evaluations and follow-up among patients with MBC.

NICE guidance

Endoscopic mastectomy and endoscopic wide local excision for breast cancer
Guidance issued
Number: IPG296
Summary:
The National Institute for Health and Clinical Excellence (NICE) has issued full guidance to the NHS in England, Wales, Scotland and Northern Ireland on endoscopic mastectomy and endoscopic wide local excision for breast cancer.
Description:
Treatment for early breast cancer usually involves surgery to remove all or part of the breast. In this keyhole procedure, part or all of the breast tissue is removed using special instruments inserted through small skin incisions. The skin envelope of the breast and nipple are left intact, ready for an implant that can be inserted during the same operation.

NICE guidelines - management of breast cancer

NICE guidelines on the management of breast cancer
Clinical guidelines 80 and 81